AD-HAFT (12+ YEARS)
IGA HAND AND/OR FOOT 0 OR 1 AT WEEK 16
(primary endpoint)1-3
- 47% of DUPIXENT patients achieved ≥75% improvement from baseline in hand lesion extent and severity (HECSI-75) vs 22% with placebo at Week 16 (P<0.05; secondary endpoint)3
All DUPIXENT-treated patients in AD-HAFT received DUPIXENT monotherapy for their hand and/or foot lesions3
- Dosing for DUPIXENT in this study was consistent with the approved dosage in the Prescribing Information1,3
See skin improvement data in other AD populations
Visible results with DUPIXENT
3-POINT IMPROVEMENT IN IGA HAND AND FOOT SCORE
Actual adult patient treated with DUPIXENT. Not a clinical trial patient. Scoring was designated by the healthcare professional. Because this was a real-world patient, other factors, including concomitant therapies, may have influenced treatment results. Individual results may vary.
A clinical responder was defined as a patient achieving IGA hand and foot 0 or 1.1
3-POINT IMPROVEMENT IN IGA HAND AND FOOT SCORE
Actual adult patient treated with DUPIXENT. Not a clinical trial patient. Scoring was designated by the healthcare professional. Because this was a real-world patient, other factors, including concomitant therapies, may have influenced treatment results. Individual results may vary.
A clinical responder was defined as a patient achieving IGA hand and foot 0 or 1.1
3-POINT IMPROVEMENT IN IGA HAND AND FOOT SCORE
Actual adult patient treated with DUPIXENT. Not a clinical trial patient. Scoring was designated by the healthcare professional. Because this was a real-world patient, other factors, including concomitant therapies, may have influenced treatment results. Individual results may vary.
A clinical responder was defined as a patient achieving IGA hand and foot 0 or 1.1
3-POINT IMPROVEMENT IN IGA HAND AND FOOT SCORE
Actual adult patient treated with DUPIXENT. Not a clinical trial patient. Scoring was designated by the healthcare professional. Because this was a real-world patient, other factors, including concomitant therapies, may have influenced treatment results. Individual results may vary.
A clinical responder was defined as a patient achieving IGA hand and foot 0 or 1.1
Watch healthcare providers discuss skin clearance with DUPIXENT
AD, atopic dermatitis; IGA, Investigator’s Global Assessment; Q2W, once every 2 weeks.